BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27437869)

  • 1. Prognostic impact of MYH9 expression on patients with acute myeloid leukemia.
    Yu M; Wang J; Zhu Z; Hu C; Ma Q; Li X; Yin X; Huang J; Zhang T; Ma Z; Zhou Y; Li C; Chen F; Chen J; Wang Y; Pan H; Wang D; Jin J
    Oncotarget; 2017 Jan; 8(1):156-163. PubMed ID: 27437869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.
    Wang J; Yu M; Guo Q; Ma Q; Hu C; Ma Z; Yin X; Li X; Wang Y; Pan H; Wang D; Huang J; Meng H; Tong H; Qian W; Jin J
    Sci Rep; 2017 Apr; 7():45960. PubMed ID: 28452374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.
    Chen YK; Hou HA; Tang JL; Jhuang JY; Lai YJ; Lee MC; Kuo YY; Chou WC; Liu CY; Lin CW; Chuang SS; Chen CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    PLoS One; 2015; 10(3):e0119831. PubMed ID: 25794001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts.
    Wang J; Li F; Ma Z; Yu M; Guo Q; Huang J; Yu W; Wang Y; Jin J
    EBioMedicine; 2018 Feb; 28():90-96. PubMed ID: 29402726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia in a child with hereditary thrombocytopenia.
    Rheingold SR
    Pediatr Blood Cancer; 2007 Jan; 48(1):105-7. PubMed ID: 16276527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.
    Ma QL; Wang JH; Yang M; Wang HP; Jin J
    J Transl Med; 2018 Mar; 16(1):68. PubMed ID: 29540187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
    Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.
    Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
    Eur J Haematol; 2016 Dec; 97(6):517-527. PubMed ID: 27096305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of MYH9 expression in resected non-small cell lung cancer.
    Katono K; Sato Y; Jiang SX; Kobayashi M; Nagashio R; Ryuge S; Fukuda E; Goshima N; Satoh Y; Saegusa M; Masuda N
    PLoS One; 2015; 10(3):e0121460. PubMed ID: 25826333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia.
    Hua S; Feng T; Yin L; Wang Q; Shao X
    J Cell Mol Med; 2021 Oct; 25(19):9331-9339. PubMed ID: 34432355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
    Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
    Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression analysis of BECN1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities.
    Zare-Abdollahi D; Safari S; Movafagh A; Ghadiani M; Tabarraee M; Riazi-Isfahani S; Gorji S; Keyvan L; Gachkar L
    Int J Lab Hematol; 2016 Apr; 38(2):125-32. PubMed ID: 26765290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.